journal article·2024-02Open access

G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I via PI3K/Akt Activation in Bladder Cancer

Xianchong Zheng, Jiawei Chen, Minhua Deng, Kang Ning, Yulu Peng, Zhenhua Liu, Xiangdong Li, Zhaohui Zhou, Huancheng Tang, Yaoying Li, Tiebang Kang, Zhuowei Liu

Advanced Science· Volume 11· Issue 7

Abstract

Abstract Immune checkpoint inhibitors (ICIs) show promise as second‐line treatment for advanced bladder cancer (BLCA); however, their responsiveness is limited by the immune evasion mechanisms in tumor cells. This study conduct a Cox regression analysis to screen mRNA‐binding proteins and reveals an association between Ras GTPase‐activating protein‐binding protein 1 (G3BP1) and diminished effectiveness of ICI therapy in patients with advanced BLCA. Subsequent investigation demonstrates that G3BP1 enhances immune evasion in BLCA cells by downregulating major histocompatibility complex class I (MHC‐I) through phosphoinositide 3‐kinase (PI3K)/Akt signaling activation. Mechanistically, G3BP1 interacts with splicing factor synergistic lethal with U5 snRNA 7 (SLU7) to form a complex with poly(A)‐binding protein cytoplasmic 1 and eukaryotic translation initiation factor 4 gamma 1. This complex stabilizes the closed‐loop structure of the mRNAs of class IA PI3Ks and consequently facilitates their translation and stabilization, thereby activating PI3K/Akt signaling to downregulate MHC‐I. Consistently, targeting G3BP1 with epigallocatechin gallate (EGCG) impedes immune evasion and sensitizes BLCA cells to anti‐programmed cell death (PD)‐1 antibodies in mice. Thus, G3BP1 and SLU7 collaboratively contribute to immune evasion in BLCA, indicating that EGCG is a precision therapeutic agent to enhance the effectiveness of anti‐PD‐1 therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Research and Splicing · Cancer-related molecular mechanisms research · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology Sun Yat‐sen University Cancer Center Guangzhou 510060 P. R. China

State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou 510060 P. R. China

Department of Urology Shunde Hospital Southern Medical University (The First People's Hospital of Shunde Foshan) Foshan 528000 P. R. China

Department of Urology Sun Yat‐sen University Cancer Center Gansu Hospital Lanzhou 730000 P. R. China

Funding

National Natural Science Foundation of China · Guangzhou Municipal Science and Technology Project

References (52)

Show source-provided references
1. 10.1038/s41571-023-00744-310.1038/s41571-023-00744-3 ↗
2. 10.1016/j.ctarc.2020.10026410.1016/j.ctarc.2020.100264 ↗
3. 10.1001/jama.2020.1759810.1001/jama.2020.17598 ↗
4. 10.1038/s41568-019-0235-410.1038/s41568-019-0235-4 ↗
5. 10.1038/s41577-022-00707-210.1038/s41577-022-00707-2 ↗
6. 10.1038/s41577-023-00842-410.1038/s41577-023-00842-4 ↗
7. 10.1016/j.semcancer.2019.06.02110.1016/j.semcancer.2019.06.021 ↗
8. 10.1016/j.molcel.2018.08.02310.1016/j.molcel.2018.08.023 ↗
9. 10.1038/s41588-019-0517-510.1038/s41588-019-0517-5 ↗
10. 10.1146/annurev-immunol-101819-07514710.1146/annurev-immunol-101819-075147 ↗
11. 10.1038/s41580-021-00417-y10.1038/s41580-021-00417-y ↗
12. 10.1038/nrg381310.1038/nrg3813 ↗
13. 10.1016/j.semcancer.2022.01.01010.1016/j.semcancer.2022.01.010 ↗
14. 10.1093/annonc/mdx51810.1093/annonc/mdx518 ↗
15. 10.1016/j.cell.2020.03.04910.1016/j.cell.2020.03.049 ↗
16. 10.1016/j.cell.2017.04.03310.1016/j.cell.2017.04.033 ↗
17. 10.1172/JCI7438210.1172/JCI74382 ↗
18. 10.3390/ijms23211341110.3390/ijms232113411 ↗
19. 10.1126/sciadv.aba541210.1126/sciadv.aba5412 ↗
20. 10.1038/s43018-021-00280-y10.1038/s43018-021-00280-y ↗
21. 10.1158/2159‐8290.CD‐23‐030610.1158/2159‐8290.CD‐23‐0306 ↗
22. 10.1038/s41418-022-01012-010.1038/s41418-022-01012-0 ↗
23. 10.3389/fimmu.2022.95786510.3389/fimmu.2022.957865 ↗
24. 10.21873/anticanres.1629210.21873/anticanres.16292 ↗
25. 10.1038/s41388-019-0683-z10.1038/s41388-019-0683-z ↗
26. 10.1172/JCI12354010.1172/JCI123540 ↗
27. 10.1158/1541-7786.MCR-19-054510.1158/1541-7786.MCR-19-0545 ↗
28. 10.1016/j.molcel.2020.01.02110.1016/j.molcel.2020.01.021 ↗
29. 10.1093/nar/gkaa37610.1093/nar/gkaa376 ↗
30. 10.1038/nature0697410.1038/nature06974 ↗
31. 10.1016/S1097-2765(00)80122-710.1016/S1097-2765(00)80122-7 ↗
32. 10.1038/s41586-018-0538-810.1038/s41586-018-0538-8 ↗
33. 10.1158/1940-6207.CAPR-09-018510.1158/1940-6207.CAPR-09-0185 ↗
34. 10.1038/s41590-018-0262-410.1038/s41590-018-0262-4 ↗
35. 10.1158/1940-6207.CAPR-08-016710.1158/1940-6207.CAPR-08-0167 ↗
36. 10.1016/j.clnu.2017.01.01410.1016/j.clnu.2017.01.014 ↗
37. 10.1128/JVI.02791-1410.1128/JVI.02791-14 ↗
38. 10.1038/s41419-019-2178-910.1038/s41419-019-2178-9 ↗
39. 10.4049/jimmunol.200111110.4049/jimmunol.2001111 ↗
40. 10.1016/j.cell.2017.07.02910.1016/j.cell.2017.07.029 ↗
41. 10.1186/s13045-022-01291-710.1186/s13045-022-01291-7 ↗
42. 10.1038/nrc83910.1038/nrc839 ↗
43. 10.1016/j.ccell.2017.04.01310.1016/j.ccell.2017.04.013 ↗
44. 10.1093/nar/gkab87310.1093/nar/gkab873 ↗
45. 10.1242/jcs.0172010.1242/jcs.01720 ↗
46. 10.1002/hep.3202910.1002/hep.32029 ↗
47. 10.1158/2159-8290.CD-20-081210.1158/2159-8290.CD-20-0812 ↗
48. 10.1073/pnas.97.16.920910.1073/pnas.97.16.9209 ↗
49. 10.1093/nar/gkw78410.1093/nar/gkw784 ↗
50. Wadsworth G. · Bio Protoc · 2018 · 8
51. 10.1093/nar/gku19910.1093/nar/gku199 ↗
52. 10.1016/j.xpro.2021.10103710.1016/j.xpro.2021.101037 ↗